SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
BIAF reported Third Quarter 2026 results. The price and volatility reaction is pending.
BIAFearnings

Earnings reactions, page 4

bioAffinity Technologies, Inc. (BIAF) Q3 FY2026 earnings

November 7, 2026 · SharpeIQ Research Desk

Reported results

  • CyPath Lung test unit sales increased 100% through Q3 compared to the first nine months of 2025.
  • CyPath Lung testing revenue for the first nine months of 2026 increased 79% to approximately $1.1 million.
  • The number of ordering physicians increased by 89% in the third quarter of 2026 compared to the third quarter of 2025.
  • Total revenue for the quarter ended September 30, 2026, was approximately $1.1 million.
  • Operating expenses for the third quarter of 2026 were approximately $4.6 million.
  • Net loss for the quarter ended September 30, 2026, was approximately $5.3 million.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-06 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →